Sendai Virus Vector for Safe iPS Cell Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating induced pluripotent stem cells (iPS cells) face challenges in producing cells with genomic information identical to patient cells, leading to immunological rejection and tumorigenic transformation due to non-specific gene insertion, and lack efficiency and uniformity in cell properties.
Innovation Solution
A Sendai virus vector system is used to reprogram differentiated cells with Oct3/4, Sox2, and Klf4 genes, ensuring these genes are not inserted into the chromosome and can be easily removed using siRNA, allowing for the generation of iPS cells with genomic information identical to the donor cell, achieving high efficiency and uniformity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If reprogramming genes are inserted into the chromosome to generate iPS cells, then reprogramming efficiency is improved, but tumorigenic transformation risk increases
Solution Approach 1:
The patent uses Sendai virus as an intermediary carrier to deliver reprogramming genes into the cytoplasm without chromosomal integration. The virus particles serve as temporary vehicles that enable efficient gene delivery while avoiding direct insertion into the host genome, thus resolving the contradiction between reprogramming efficiency and tumorigenic risk
Solution Approach 2:
The patent extracts the reprogramming genes from their chromosomal integration context and delivers them directly to the cytoplasm via Sendai virus particles. This separation of gene delivery from chromosomal insertion allows efficient reprogramming while eliminating the tumorigenic risk associated with random genomic integration
2Manufacturing precision
If multiple reprogramming genes are delivered separately, then gene expression control is improved, but manufacturing complexity increases
Solution Approach 1:
The patent combines multiple reprogramming genes (Oct3/4, Sox2, Klf4, and c-Myc) into a single Sendai virus vector system. This merging approach simplifies the manufacturing process by enabling simultaneous delivery of all reprogramming factors through one viral preparation, while still maintaining individual gene expression control within the unified vector system
3Quantity of substance
If tissue cells are collected through surgery to generate iPS cells, then cell source availability is improved, but patient stress and procedural risk increase
Solution Approach 1:
The patent enables the patient's own somatic cells to serve as the source for generating personalized iPS cells. By using minimally invasive collection methods, the patient's cells are harvested with minimal stress, then reprogrammed ex vivo to create therapeutic cells that will be transplanted back into the same patient, eliminating the need for donor organs and reducing procedural risks
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables the production of iPS cells with genomic information identical to the donor cell, avoiding immunological rejection and tumorigenic transformation, and achieving high efficiency and uniformity, thus enhancing safety and applicability in regeneration therapies.
Implementation Method 1
a Sendai virus vector system is used to reprogram differentiated cells with Oct3/4, Sox2, and Klf4 genes
Implementation Method 2
these genes can be easily removed using siRNA
Data Source
Figure 1
Figure 2
Figure 3~3B
AI summary
Cell reprogramming genes are loaded on a sustained expression-type Sendai virus vector free of an activity of incorporating exogenous genetic information into a chromosome. The genes are transfected into a normal differentiated cell via the vector, and expressed. Then, a vector genomic RNA including the genes is removed from the cell to establish an induced pluripotent stem cell. The Sendai virus vector makes it possible to generate an induced pluripotent stem cell having genomic information identical to that of a donor individual of the differentiated cell, in a significantly simple and efficient manner and in a safe manner with less risk of tumorigenic transformation. Thus, the Sendai virus vector can serve as an important tool for performing cell replacement therapies in a safe and efficient manner though the provision of useful induced pluripotent stem cells.